In recent years, significant progress has been made in the field of gene editing techniques, such as CRISPR-Cas9, allowing precise modifications of DNA to correct genetic defects. Furthermore, advancements in viral vector technologies have enabled more efficient and targeted delivery of therapeutic genes into patients' cells.

The Cell And Gene Therapy Market has witnessed a remarkable surge in emerging technologies and developments, positioning it at the forefront of medical advancements. These innovative therapies involve the manipulation of living cells and genes to treat a wide range of diseases, offering personalized and potentially curative treatment options.

Additionally, the discovery of induced pluripotent stem cells (iPSCs) has opened up new avenues for generating patient-specific cells for transplantation, reducing the risk of immune rejection. Moreover, the regulatory environment has adapted to accommodate these groundbreaking therapies, leading to an increasing number of approved cell and gene therapies for various conditions.